Maven Equity Finance has committed £1.6 million to eviFile through the Northern Powerhouse Investment Fund II. The funding supports eviFile’s expansion in digital assurance software for the UK’s built environment.
eviFile provides cloud-based solutions that record, verify, and manage data for major infrastructure projects. Its platform connects field data with project reporting to improve compliance, quality, and safety across sectors such as rail, energy, utilities, and construction. Clients include Network Rail, Drax Power, Alstom, Siemens, and SPL Powerlines.
The company has experienced strong growth over the past year, driven by regulatory drivers such as the Building Safety Act and increased digital adoption across the UK infrastructure market. It is now integrating artificial intelligence into its platform to automate quality checks, predict risks, and enhance reporting accuracy.
Nick Halliday, Founder of eviFile, said: “This is a really exciting time for eviFile. Our platform has been built to help clients take control of their project workflows with trusted data and real-time insight. Partnering with Maven gives us the support to scale faster and further. We’re looking forward to what this next stage brings and are confident that this partnership will help us deliver even more value and a better solution to our clients.”
The investment will fund research and development, expand sales and marketing teams, and accelerate the rollout of new AI capabilities. David Nixon, Senior Investment Manager at Maven Capital Partners, said: “eviFile has a highly scalable, proven operating model driven by a strong management team with a clear vision. With the significant uptick in digitalisation in the sector, the business is well positioned for continued growth within several verticals. We’re delighted to support Nick and the team as they execute their ambitious plans.”
Maven’s involvement is part of its broader strategy to scale regional innovators, with previous NPIF II investments spanning advanced engineering, fintech, life sciences and manufacturing.
